Berodual® MDI

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 3

Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT02173782

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 1998-02-28Updated: 2014-07-14

Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma

CompletedNCT02182505

Boehringer IngelheimAsthma

Start: 1998-09-30Updated: 2014-07-14